331 related articles for article (PubMed ID: 15305382)
1. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
[TBL] [Abstract][Full Text] [Related]
2. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
3. Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions.
Doherty SD; Ni X; Doherty CB; Jones D; Zhao X; Owen LB; Duvic M
Arch Dermatol Res; 2006 Dec; 298(7):353-6. PubMed ID: 17021762
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
5. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
6. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides.
Cetinözman F; Jansen PM; Vermeer MH; Willemze R
Arch Dermatol; 2012 Dec; 148(12):1379-85. PubMed ID: 23247480
[TBL] [Abstract][Full Text] [Related]
8. The role of IL-32 in cutaneous T-cell lymphoma.
Suga H; Sugaya M; Miyagaki T; Kawaguchi M; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Invest Dermatol; 2014 May; 134(5):1428-1435. PubMed ID: 24226419
[TBL] [Abstract][Full Text] [Related]
9. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
10. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
Wong HK
Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
[TBL] [Abstract][Full Text] [Related]
11. Deciphering Tumor Cell Evolution in Cutaneous T-Cell Lymphomas: Distinct Differentiation Trajectories in Mycosis Fungoides and Sézary Syndrome.
Jiang TT; Cao S; Kruglov O; Virmani A; Geskin LJ; Falo LD; Akilov OE
J Invest Dermatol; 2024 May; 144(5):1088-1098. PubMed ID: 38036289
[TBL] [Abstract][Full Text] [Related]
12. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
13. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the IL-31 pathway in Mycosis fungoides and Sézary syndrome.
Möbs M; Gryzik S; Haidar A; Humme D; Beyer M; Vandersee S
Arch Dermatol Res; 2015 Aug; 307(6):479-85. PubMed ID: 25488078
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenesis of cutaneous lymphomas.
Stadler R; Stranzenbach R
Exp Dermatol; 2018 Oct; 27(10):1078-1083. PubMed ID: 29862563
[TBL] [Abstract][Full Text] [Related]
17. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
Wong HK
G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
19. BCL2 and JUNB abnormalities in primary cutaneous lymphomas.
Mao X; Orchard G; Lillington DM; Child FJ; Vonderheid EC; Nowell PC; Bagot M; Bensussan A; Russell-Jones R; Young BD; Whittaker SJ
Br J Dermatol; 2004 Sep; 151(3):546-56. PubMed ID: 15377339
[TBL] [Abstract][Full Text] [Related]
20. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]